on24.com
With the continued pressure to reduce costs through innovations and efficiencies all while delivering faster sample results, the use of an On-line Water Bioburden Analyzer (OWBA) is one way companies can meet these demands. OWBA technology has the flexibility to be used for purified water, water for injections or even cleaning verifications and provides real time microbial detection as an early warning for system health. The benefits for using an OWBA include the potential for energy savings through reduced loop sanitation, labor cost reduction and improved product quality and process understanding.
Watch Now
Pharmtech
Developing and bringing a new drug to market is a long, expensive, and uncertain process. It’s even more complicated when it comes to complex products such as modified-release products and biologics. Bio/pharma companies can adopt proven strategies to increase the success of a product launch: cross-functional team collaboration, risk understanding and mitigation, a dedicated team, and the right project management tools. In this webcast, experts will share insights gained from decades of experience launching new products and discuss case studies demonstrating how to reliably bring products to market quickly without sacrificing compliance.
Watch Now
Charles River
Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.
Watch Now
pharmexec
We are entering a new era in which real-world evidence is transforming how drugs are developed, approved, and commercialized. As FDA leads the change with a 3-year strategy—the Framework for FDA’s Real-World Evidence Program—the industry is launched on a shared learning process to understand where and when RWE can support regulatory decision-making. This webcast brings together industry experts in research and pharma to explore how forward-thinking pharmaceutical organizations are adopting new approaches for the use of RWE in drug development and approval.
Watch Now